TTrialPathMatch Me to Trials
← Back to trials
RecruitingObesity

Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension

Eligible age

18–79 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance.

Sponsor: University of Kansas Medical Center

You may qualify if…

  • 1. Obese: BMI \>25 m/kg2
  • 2. Elevated insulin resistance: HOMA-IR \> 2.5 (calculation based on fasting glucose and insulin concentrations in blood)
  • 3. Middle-aged: 35-65 years
  • 4. Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
  • 5. Able and willing to provide written informed consent

You may not qualify if…

  • 1. Currently taking a statin or antihypertension medication
  • 2. Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
  • 3. Hypertension: \>130/80 mmHg
  • 4. History of heart disease (e.g., myocardial infarction, stent)
  • 5. History of vascular disease (e.g., bypass, stroke)
  • 6. Individuals with narrow angle glaucoma
  • \-

Where it's recruiting

Kansas

Kansas City

Source: ClinicalTrials.gov · NCT06626113 · last updated 2024-10-03

Transduction of Sympathetic Neural Activity in Human Obesity Without H · TrialPath